S.L.A Pharma AG Unveiled Top-Line Data from Phase 2 Study

S.L.A. Pharma AG has announced medically and statistically considerable top-line data from their Phase 2 double blind randomised placebo managed study. The research was designed to assess the security and efficacy of 4 doses of Nalcol™, a novel oral strength of naloxone (2.5, 5, 10, and 20 mg), in curing opioid induced constipation (OIC) in affected individuals with constant non-cancer pain.

Statistical significance for growing spontaneous bowel movements (SBMs) against panacea and baseline were actually displayed by different doses of Nalcol™. Raises in SBMs were actually dose-related with clinically considerable effects (greater than 3 SBMs per week) seen in the 5, 10, and 20 mg doses. Affected individuals obtaining the 20 mg Nalcol™ dose displayed the best benefit with their SBMs, increasing because of an average of 1 per week to over 6 per week.

The large amount of affected individuals obtaining clinical benefit within the 5, 10 and 20 mg therapy groups was above carefully that of a typical placebo group. Essencially clinical benefits were actually sustained through the entire treatment intervals.